Dow Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Dow Inc trades at $28.42 (market cap $20.65B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.59 (market cap $6.04B). The key difference: Dow Inc is far larger — about 3.4× Iovance Biotherapeutics Inc. Common Stock's market cap, and Dow Inc pays a 4.9% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| DOW | IOVA | |
|---|---|---|
Market Cap | $20.65B | $6.04B |
Volume | 14,126,943 | 14,805,993 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $14.82 |
52-Week Low | $20.65 | $1.81 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $36.34B | $5.97B |
Dividend Yield | 4.9% | — |
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.80, up 3.71% today, near the analyst low target of $28.00. The stock shows a bullish technical signal despite negative profitability, with ROE at -7.86% and net income margin at -3.13%. Recent earnings have beaten expectations, but revenue declined to $39.97B in 2025. Cash flow improved to $1.69B net in 2025, though operating cash flow remains pressured.
Outlook is mixed: analyst consensus is a hold with a $34.22 price target, implying 19% upside, but weak margins and declining revenue pose risks. The dividend yield offers income support, but investors face headwinds from cyclical chemical demand and high debt levels, with debt-to-asset ratio rising to 29.87% in 2025.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →